Table 1.

Antitumor activity (GI₅₀/μM)^a data for the substituted benzyl and phenethyl carbamate derivatives of MMB (7a-c, 7h, 7i and 7k) from the NCI-five dose human cancer cell panel assay

	1^b	7a	7b	7c	7h	7i	7k

Panel/cell line	GI₅₀	GI₅₀	GI₅₀	GI₅₀	GI₅₀	GI₅₀	GI₅₀
Leukemia
CCRF-CEM	7.94	0.47	0.26	0.48	0.34	1.98	0.27
HL-60(TB)	5.01	1.69	0.26	1.61	1.36	2.34	1.06
K-562	19.9	1.57	0.37	0.82	0.61	3.08	0.53
MOLT-4	15.8	2.00	0.28	2.53	2.09	2.61	1.69
RPMI-8226	7.94	1.8G	0.26	1.77	0.91	2.85	0.62
SR	nd	0.32	0.30	0.67	0.51	2.07	0.43
Lung Cancer
A549/ATCC	nd	2.58	2.43	3.07	7.28	13.2	2.59
EKVX	nd	2.06	1.29	1.98	1.78	7.45	1.54
HOP-62	nd	3.06	4.81	3.69	4.39	12.2	1.99
HOP-92	12.5	1.42	0.24	1.49	1.84	1.99	1.28
NCI-H226	nd	2.02	0.48	2.11	1.57	4.11	1.72
NCI-H23	nd	1.84	0.55	1.74	1.86	4.34	1.72
NCI-H322M	nd	4.72	nd	nd	nd	12.6	nd
NCI-H460	nd	3.01	2.74	3.73	3.94	12.2	2.06
NCI-H522	5.01	0.34	0.17	0.35	1.02	1.82	1.16
Colon Cancer
COLO 205	15.8	1.35	0.24	1.75	1.55	1.94	1.82
HCC-2998	nd	1.94	0.51	1.82	1.68	2.48	1.71
HCT-116	10.0	0.77	0.19	0.54	0.71	1.34	0.47
HCT-15	nd	0.77	0.24	1.04	1.02	1.74	1.01
HT29	nd	1.20	0.26	1.22	1.14	2.15	1.32
KM12	nd	2.80	2.35	3.53	4.27	8.36	1.95
SW-620	15.8	1.12	0.22	0.76	0.52	2.51	0.71
CNS Cancer
SF-268	nd	2.46	0.75	2.20	1.78	10.6	1.56
SF-295	nd	7.78	10.8	5.02	7.26	13.5	3.81
SF-539	19.9	1.54	0.32	1.53	1.49	1.79	1.46
SNB-19	nd	5.32	0.70	1.57	1.43	8.65	1.39
SNB-75	50.1	1.99	0.74	2.44	1.47	4.09	1.20
U251	nd	3.16	0.96	2.20	nd	11.1	1.40
Melanoma
LOX IMVI	7.94	0.54	0.27	1.43	1.34	1.38	1.18
MALME-3M	12.5	1.86	0.20	1.89	1.84	2.44	2.09
M14	nd	1.64	0.19	1.10	1.29	1.98	1.26
MDA-MB-435	nd	1.99	0.42	1.70	1.58	3.53	1.58
SK-MEL-2	nd	1.66	1.18	1.71	1.73	8.97	1.58
SK-MEL-28	nd	1.47	0.27	1.52	1.35	1.99	1.47
SK-MEL-5	nd	3.48	1.20	2.86	1.84	6.23	1.71
UACC-257	nd	1.54	0.32	1.48	1.53	2.49	1.63
UACC-62	nd	0.66	nd	nd	nd	1.25	nd
Ovarian Cancer
IGROV1	19.9	2.12	0.29	1.57	1.26	2.61	1.08
OVCAR-3	19.9	1.01	0.28	0.87	0.99	2.19	0.98
OVCAR-4	nd	1.70	0.49	1.78	1.78	3.41	1.56
OVCAR-5	nd	1.82	1.46	2.29	2.25	2.65	1.96
OVCAR-8	nd	1.60	0.49	2.45	2.26	2.77	1.49
NCI/ADR-RES	nd	2.98	1.79	2.26	2.95	10.0	2.26
Renal Cancer
786-0	nd	1.70	0.18	1.16	1.37	1.76	1.04
A498	nd	2.11	0.72	3.23	2.35	4.52	2.07
ACHN	nd	1.29	0.27	1.27	1.12	1.72	1.32
CAKI-1	10.0	1.59	0.31	1.38	1.19	2.52	1.42
RXF 393	12.5	0.68	0.19	1.04	0.67	1.55	1.20
TK-10	nd	1.66	0.35	1.79	1.61	2.73	1.73
UO-31	nd	1.51	0.16	1.68	1.39	1.76	1.55
Prostate Cancer
PC-3	nd	2.72	1.87	3.13	2.30	8.08	1.73
DU-145	nd	0.72	0.37	0.69	0.89	1.92	0.77
Breast Cancer
MCF7	15.8	0.58	0.27	0.49	0.49	1.89	0.41
MDA-MB-231	nd	1.61	0.62	1.47	1.56	2.02	1.42
HS 578T	nd	4.12	0.79	3.40	3.43	13.8	2.41
BT-549	nd	1.57	0.20	1.25	1.51	2.12	1.10
T-47D	nd	1.85	0.34	2.01	1.61	2.47	1.38
MDA-MB-468	nd	0.58	0.24	0.66	0.85	1.55	0.84
Average GI₅₀	14.96	1.92	0.86	1.80	1.82	4.4	1.44

GI₅₀ values <1μM are bolded; nd: not determined;

GI₅₀: concentration of drug resulting in a 50% reduction in net cell growth, as compared to cell numbers on day 0.

5-dose NCI cancer cell screening data for PTL (1).[10]